Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting

References

• Isaacs JD, Cutolo M, Keystone EC, et al. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. J Intern Med. 2016;279:41–59.
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Ceribelli A, Marotto D, et al. Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev. 2019;18:583–592.
   PubMed Web of Science ®Google Scholar
• Kuek A, Hazleman BL, Ostör AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83:251–260.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based multinational assessment of psoriasis and psoriatic arthritis survey. J Eur Acad Dermatol Venereol. 2015;29:2002–2010.
   PubMed Web of Science ®Google Scholar
• Scriffignano S, Perrotta FM, De Socio A, et al. Role of comorbidities in spondyloarthritis including psoriatic arthritis. Clin Rheumatol. 2019;38:3–10.
   PubMed Web of Science ®Google Scholar
• Olivieri I, D’Attino RM, Gualberti G, et al. THU0398 observational study on the quality of life of Italian axial spondyloarthritis patients (QUASAR): baseline data. Ann Rheum Dis. 2016;75:332.
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Cazzaniga S, Colombo P, et al. Psoriasis incidence and lifetime prevalence: suggestion for a higher mortality rate in older age-classes among psoriatic patients compared to the general population in Italy. Acta Derm Venereol. 2019;99:400–403.
   PubMed Web of Science ®Google Scholar
• D V O, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665.
   Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499–510.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2016;2017(76):978–991.
   Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774–790.
   PubMed Web of Science ®Google Scholar
• So A, Inman RD. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32:453–471.
   PubMed Web of Science ®Google Scholar
• Uhrenholt L, Schlemmer A, Hauge E-M, et al. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the Biological Dose Optimisation (BIODOPT) trial) Internet]. 2019 [cited 2019 Dec 5];9. Available from:. BMJ Open: https://bmjopen.bmj.com/content/9/7/e028517
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther. 2018;35:1333–1355.
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines. [Internet]. 2010. [cited 2019 Dec 5] Available from: https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdf.
   Google Scholar
• Ogata A, Kaneko M, Narukawa M. Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon. Plos One. 2019;14:e0218534.
   PubMed Web of Science ®Google Scholar
• Iskandar IYK, Ashcroft DM, Warren RB, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British association of dermatologists biologic interventions register (BADBIR). Br J Dermatol. 2017;176:1297–1307.
   PubMedGoogle Scholar
• Perrone V, Sangiorgi D, Naclerio M, et al. PSY119 - TREATMENT PATTERN ANALYSIS AND HEALTHCARE RESOURCE CONSUMPTION ON PATIENTS AFFECTED BY PSORIASIS IN APULIA REGION (ITALY). Value Health. 2018;21:S456.
   PubMedGoogle Scholar
• Rencz F, Kemény L, Gajdácsi JZ, et al. Use of biologics for psoriasis in Central and Eastern European countries. J Eur Acad Dermatol Venereol. 2015;29:2222–2230.
   PubMed Web of Science ®Google Scholar
• Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. Internet]. 2018 [cited 2020 Apr 27];4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109814/
   Google Scholar
• Barczyńska TA, Węgierska M, Żuchowski P, et al. Coexistence of rheumatoid arthritis and ankylosing spondylitis. Reumatologia. 2015;53:279–285.
   PubMedGoogle Scholar
• Esposito M, Gisondi P, Conti A, et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017;31:863–869.
   PubMed Web of Science ®Google Scholar
• Faccendini P, Cantillo E, Fanizza C, et al. Analisi di Farmacoutilizzazione dei Trattamenti Biologici Nelle Malattie Infiammatorie Immunomediate Croniche: I Risultati di Uno Studio Osservazionale Retrospettivo Condotto in un Centro Ospedaliero del Centro Italia. Global Reg Health Technol Assess. 2017;4:grhta.5000271.
   Google Scholar
• Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, et al. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Expert Rev Pharmacoecon Outcomes Res. 2015;15:851–858.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–519.
   PubMed Web of Science ®Google Scholar
• Gazzetta Ufficiale- DETERMINA 26 ottobre. 2016 [Internet]. [cited 2020 Jul 17]. Available from: https://www.gazzettaufficiale.it/eli/id/2016/11/11/16A07913/sg.
   Google Scholar
• Stoner KL, Harder H, Fallowfield LJ, et al. Intravenous versus subcutaneous drug administration. which do patients prefer? Syst Rev Patient. 2015;8:145–153.
   Google Scholar
• Murage M, Tongbram V, Feldman S, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. PPA. 2018;12:1483–1503.
   Web of Science ®Google Scholar
• Anghel L-A, Farcaş A, Oprean R. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. PPA. 2018;12:1151–1166.
   Google Scholar